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Background: The aim of this study was to measure the body composition in adults with newly diagnosed type 2
diabetes mellitus and to explore the effect of metformin therapy on the various components of body composition,
insulin sensitivity, and glucose homeostasis.
Methods: This was an observational study consisted of 51 newly diagnosed people with type 2 diabetes on
1000 mg metformin twice daily for 6 months. The body composition of each subject was measured by dual energy
X-ray absorptiometry at enrollment and 24 weeks after metformin mono-therapy. Sarcopenia was defined and
compared based on the ratio of appendicular skeletal muscle and height squared, skeletal muscle index and
residual methods.
Homeostasis model assessment-insulin resistance and Quantitative Insulin Sensitivity Check Index were used for
estimating insulin sensitivity. The level of physical activity was assessed using self-administered International physical
Activity questionnaire.
Results: Forty one subjects (80.4%) completed the study. The mean age of the participants was 52.67 ± 10.43 years.
Metformin treatment was associated with a significant decrease in total fat mass (−1.6 kg, P = 0.000). By week 24,
the lean to fat ratio increased (P = 0.04) with men showing greater significant changes. Twenty percent of the
female participants were detected to have sarcopenia.
In addition, there was a significant improvement of glucose homeostasis and insulin sensitivity.
Conclusions: Metformin therapy results in significant improvement in body composition and insulin sensitivity of
adults with newly diagnosed type 2 diabetes. Furthermore, sarcopenia begins in women with diabetes much earlier
than expected as an age related phenomenon.
Keywords: Diabetes Mellitus, Type 2, Insulin Sensitivity, Insulin Resistance, Sarcopenia, Dual Energy X-ray
AbsorptiometryIntroduction
Type 2 diabetes is a prevalent disease with substantial
morbidity and mortality [1,2]. It is now considered as a
global health problem with serious economic burdens [3].
People with type 2 diabetes are usually overweight or
obese [4]. Metformin, the most widely used biguanides
for the treatment of type 2 diabetes mellitus [5], induces
weight stabilization or small weight loss in adults with
diabetes [6]. This might be due to reduction of insulin* Correspondence: khamseh.m@iums.ac.ir
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unless otherwise stated.resistance and subsequent hyperinsulinemia [7,8]. It has
also reported that in non-diabetic subjects with risk fac-
tors for type 2 diabetes mellitus, metformin modifies
body composition by decreasing total fat content and in-
creasing lean mass and water content [9].
Measuring body composition by dual energy X-ray ab-
sorptiometry (DEXA) is a noninvasive and valid method
[10] that allows separation of the body mass into bone
mass, fat mass (FM), and fat-free mass (FFM). It can also
give estimation for the regional body composition [11].
Insulin resistance or insulin sensitivity were estimated
using the homeostatic model assessment-insulin resistancetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Check Index (QUICKI) methods [9].
The aim of this study was to investigate the body com-
position, the alterations happened by metformin, and
their impact on insulin resistance, insulin sensitivity, and
metabolic control in adults with newly diagnosed type 2
diabetes mellitus.Method and materials
Study design
This was a 24-week, prospective, non-interventional, obser-
vational study of 51 newly diagnosed people with type 2
diabetes who had been initiated metformin to investigate
the body composition, the alterations happened by met-
formin, and their impact on insulin resistance, insulin sensi-
tivity, and metabolic control in routine clinical practice.
G-power software was used to calculate the sample size.
Assuming the mean and SD of fat weight [9] as one of the
component of body composition that was important in this
study, 38 patients will provide 90% power at a 2-sided with
significance level of 0.05. Allowing for a 20% dropout rate,
the number of subjects required for the study was 46 pa-
tients. Key eligibility requirements were fasting plasma glu-
cose concentration of ≥7.0 mmol/L (≥126 mg/dl) or a 2-h
plasma glucose concentration of 11.1 mmol/L (≥200 mg/
dL) after 75 g glucose by mouth, or glycated hemoglobin
(HbA1c) ≥6.5% (48 mmol/mol).
The diagnosis was confirmed by repeating one of the
mentioned methods on a different day. Subjects with a
diagnosis of cardiac, renal, pulmonary, endocrine and
hepatic disease, or any other systematic intercurrent ill-
ness that might alter body composition were excluded.
They were excluded if they had a GFR < 70 and/or an
alanine aminotransferase (ALT) that exceeds 1.5 times
the upper limit of normal. Those with prior treatment
with oral glucose lowering drugs and/or insulin were
also excluded.Patients
Fifty one subjects met the inclusion criteria and were en-
rolled in the study. Weight measurement was done using
a calibrated digital scale (Seca gmbh & co. kg. Germany).
A stadiometer (Seca gmbh & co. kg. Germany) calibrated
before each measurement, was used for height measure-
ment. Abdominal and hip circumferences were assessed
by a trained nurse, using a cloth tape. The waist was de-
fined at the midpoint between the highest point of the iliac
crest and the lowest part of the costal margin in the mid-
axillary line, and the hip was measured at the level of the
greater femoral trochanters. These measurements were
used for calculating the body mass index (BMI), and the
waist to hip ratio (WHR).Body composition and DXA assessment procedures
Body composition was assessed by Hologic whole body
DEXA systems (QDR4500A, Hologic, Waltham, MA, USA;
software version 8.21) A total body scan was performed at
baseline and again at the end of the study. A standardized
procedure for patient positioning and utilization of the
QDR software was used. Total body FFM, FM, lean mass
(LM), and percent fat were analyzed using Hologic version
8.21 software for tissue area assessment. Total body FFM
was defined as lean soft tissue mass plus total body bone
mineral content. Android FM was defined as adipose de-
position around the abdomen; whereas, gynoid FM was
adipose tissue accumulating around the hips. Appendicular
skeletal muscle (ASM) was calculated as the sum of skeletal
muscle mass in arms and legs. ASM/h2 was computed as
the indicator of relative ASM. The scanner was calibrated
daily against a spine calibration block and step phantom
block supplied by the manufacturer. In addition, a whole
body phantom was scanned weekly to assess any machine
drift over time.
Skeletal muscle index (SMI) was analyzed based on
the equation established by Janssen et al. (SMI = 100 ×
skeletal muscle mass/body mass) [13].
The predicted percentage of fat by sex, BMI, and age
was calculated using the formulas proposed by Gallagher
et al. [14].
Percentage of FM= 76.0 – 1097.8 (BMI−1) – 20.6 (Sex) +
0.053 (Age) + 95.0 (Asian) (BMI−1) – 0.044 (Asian) (Age) +
154 (Sex) (BMI−1) + 0.034 (Sex) (Age)
These formulas reported a correlation coefficient of
about 0.90 and standard error of estimation of about 4%.
Variables were defined as sex = 1 for male and 0 for fe-
male; Asian = 1 for Asian and 0 for other races [14].
Physical activity assessment
At baseline, the level of physical activity was assessed with
self-administered International Physical Activity Question-
naire (IPAQ). All of the participants were asked to have
and maintain ≥ 30 min/day or 150 min per week of
moderate-intensity such as walking or 75 min per week of
vigorous aerobic physical activity or an equivalent combin-
ation of the two, based on recommendations of standards
of medical care in diabetes 2012 [15]. Furthermore, each
participant met a dietitian who administered a personal-
ized isocaloric diet.
Interventions and treatment
After an overnight fast of at least 8 hours, blood samples
were obtained for measurement of fasting blood sugar
(FBS) using a glucose analyzer (YSI 2700 Select, YSI, Inc.,
Yellow Springs, OH), fasting insulin (IMX assay, Abbott
Laboratories, North Chicago, IL), and HbA1c using ion
exchange chromatography (DS5 Analyzer, Drew Scientific
limited, Cumbria, United Kingdom).
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HOMA-IR index = Fasting insulin (μU/mL) × Fasting glu-
cose (mg/dL)/405.
Insulin sensitivity was determined by the quantitative
insulin sensitivity check index (QUICKI) calculated as
1
log of fasting insulin μU=mLð Þ þ log of fasting glucose mg=dLð Þ
Once baseline assessments were completed, metformin
(Iran, Arya Pharmaceutical Company) was prescribed to
all of the eligible subjects with a starting dose of
1000 mg/day.
After 12 weeks, the participants were reevaluated re-
garding their lifestyle and adherence to the medication.
The metformin dose was titrated, if needed, based on
HbA1c obtained after 12 weeks of starting treatment.
The participants were followed by another 12 weeks.Table 1 Descriptive baseline characteristics of the
participants
Female (n = 30) Male (n = 21) P-Value
Age (y) 52.3 ± 10.58 53.2 ± 10.45 0.98
Weight (kg) 74.03 ± 10.82 81.09 ± 12 0.05
BMI (kg/m2) 30.06 ± 4.3 27.78 ± 3.27 0.04
Waist (cm) 101.83 ± 9.18 101.52 ± 7.6 0.90
WHR 0.95 ± 0.05 0.96 ± 0.04 0.26
HbA1c (%) 7.95 ± 2.19 8.45 ± 1.92 0.46
HOMA-IR 3.33 ± 1.53 3.95 ± 3.44 0.74
QUICKI 0.33 ± 0.02 0.33 ± 0.03 0.74
Independent sample t-test and Mann Whitney U-test were used.
BMI: Body Mass Index
WHR: Waist to Hip Ratio
HbA1c: Glycosylated Hemoglobin
HOMA-IR: Homeostatic Model Assessment-Insulin Resistance
QUICKI: Quantitative Insulin Sensitivity Check IndexSarcopenia classification
We compared the three methods used for identification
of sarcopenia. Based on the definition by Baumgartner
and colleagues, ASM/h2 was calculated as the ratio of
ASM (kg) and height squared (m2) [16]. Participants
were categorized as having sarcopenia based on ASM/h2
cut-points defined in previous studies (>2 SD below sex-
specific means of normal reference population: 7.26 kg/
m2 for men and 5.45 kg/m2 for women [16].
Considering SMI method, Class I sarcopenia was
established in the participants whose SMI were within
one to two SDs below the sex-specific mean of young
adults. Class II sarcopenia was ascertained in the partici-
pants whose SMI were lower than two SDs below the
sex-specific mean of young adults.
The residuals method is based on the regression model
recommended by Newman et al. [17]. Linear regression
equations using height (m) and FM (kg) to predict ASM
were determined for male and female, respectively. The re-
siduals of the regression were applied to identify partici-
pants whose ASM were lower or higher than the predicted.
The 20th percentile of the distribution of residuals was used
as the cutoff points for sarcopenia. Separate models were
fit for men (ASM (kg) = −30.239 + 30.105 × height (m) +
0.141 × fat mass (kg)) and women (ASM (kg) = −15.407 +
17.595× height (m) + 0.162 × fat mass (kg).
The study was carried out at Endocrine Research Centre,
Institute of Endocrinology and Metabolism. Ethical ap-
proval was obtained from the institutional review board of
Institute of Endocrinology and Metabolism affiliated to
Iran University of Medical Sciences (525MT/2011). All
participants signed a written informed consent. Partici-
pants were free to withdraw at will at any time. If they
withdrew, the data collected were used for analysis until
the point when consent was withdrawn. The primary end-
points were changes in body composition and BMI by
the end of 24 weeks. Secondary endpoints were insulinresistance, insulin sensitivity, HbA1c, fasting insulin, and
fasting blood sugar.
Statistical analysis
IBM SPSS for Windows Version 19 (IBM Corp., Armonk,
NY, USA) was applied for the statistical analysis. The data
were analyzed anonymously. Descriptive statistics (means
and SDs) were used to describe key clinical and demo-
graphic characteristics. Normal assumptions were checked
by looking at the Normal plot, or Frequency histogram
with as well as Kolmogorov-Smirnov test. In case of nor-
mal distribution, we used parametric statistical test while
we used non-parametric statistical tests in case of non-
normal distribution. The relationship between age and
ASM/h2, SMI, and total fat mass in men and women were
illustrated by scatter plots and fit lines. Based on ASM/h2,
SMI, and residuals methods, the prevalence of sarcopenia
in men and women were calculated.
The comparison of the variables before and after the
treatment was performed using the paired t-test or
Wilcoxon. The relationships between variables were
shown using Spearman’s Correlation coefficient. The or-
dinal variables were compared between two groups via the
independent t-test or Mann–Whitney U-test. A P-value <
0.05 was considered statistically significant.
Results
Of the 51 participants, a total of 41 subjects (80.4%) had
good adherence to the study protocol and completed the
6-month study. Baseline anthropometric and laboratory
indices did not significantly differ between those who fin-
ished the study and those who withdrew (data not shown).
The mean age was 52.67 ± 10.43 years (range 26 –
71 years) and 59% were female. BMI was higher in women
than in men. Table 1 illustrates descriptive baseline char-
acteristics of the participants.
Table 2 Changes in anthropometric variables by the end of the study
Characteristics Female P-value Male P-value
Week 0 Week 24 Week 0 Week 24
Weight (kg) 74.03 ± 10.82 72.84 ± 10.76 0.00 81.09 ± 12 77.46 ± 15.07 0.09
BMI (kg/m2) 30.06 ± 4.3 29.44 ± 4.6 0.00 27.78 ± 3.27 27.18 ± 4.4 0.14
Waist (cm) 101.83 ± 9.18 99 ± 12.05 0.18 101.52 ± 7.6 99.46 ± 10.65 0.35
WHR 0.95 ± 0.05 0.95 ± 0.14 0.35 0.96 ± 0.04 0.95 ± 0.04 0.93
Paired t-test and Wilcoxon test was used.
BMI: Body Mass Index
WHR: Waist to Hip Ratio
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ables by the end of the study. A significant sex difference
was also noted (P = 0.000), with women showing a
greater mean decrease in BMI (−0.62 Kg/m2) at 24 week
with Metformin treatment than men (−0.58 Kg/m2).
BMI was significantly related to total, gynoid, and an-
droid FM at baseline and the end of the study (P =
0.000). Waist circumference and WHR did not differ sig-
nificantly by the end of the study in men and women.
Waist circumference was mostly correlated with total
FM (P = 0.000) and android FM (P = 0.000).
The level of physical activity, classified as low, moder-
ate, or high was assessed for all of the participants. It
showed no significant difference by the end of the study,
although, by week 24, more subjects reported higher
level of physical activity (P = 0.082).Primary endpoints
At baseline and at the end of the study, a significant sex
difference was shown with women having higher level of
gynoid FM and total FM (P-values < 0.05).Table 3 Body composition parameters at baseline and 24 wee
Female
Week 0 (n = 30) Week 24 (n = 2
Android fat mass (kg) 2.80 ± 0.77 2.63 ± 0.78
Gynoid fat mass (kg) 4.60 ± 1.02 4.42 ± 1.02
Android fat mass
Gynoid fat mass 0.61 ± 0.12 0.60 ± 0.13
Trunk/limb fat 1.02 ± 0.15 1.01 ± 0.15
Fat mass/h2 (kg/m2) 12.45 ± 3.1 11.88 ± 2.98
Appendicular lean mass/h2 (kg/m2) 7.49 ± 0.91 7.18 ± 1.03
Appendicular lean mass/W 0.24 ± 0.02 0.24 ± 0.02
SMI 0.03 ± 0.01 0.03 ± 0.01
Total fat mass (kg) 29.91 ± 6.91 28.68 ± 6.58
Percentage of Fat (%) 43.03 ± 5.35 41.54 ± 5.77
Total lean mass (kg) 41.95 ± 4.86 40.79 ± 5.12
Lean/Fat ratio 1.45 ± 0.31 1.48 ± 0.33
Paired t-test and Wilcoxon test was used.
h2: Height Squared
W: Weight
SMI: Skeletal Muscle IndexBy week 24, statistically significant reduction was ob-
served in the total FM (−1.6 kg; 95% CI = −2.39 to 0.84;
P =0.000) and percentage of FM (P = 0.000). There was
also a significant increase in the proportion of lean/fat
ratio in total study population (+0.10; 95% CI = 0.005 to
0.199; P = 0.04) that was more pronounced in men.
This was observed despite a reduction in LM (−1.07 kg,
95% CI = 1.78 to −0.35, P = 0.00) by the end of the study.
ASM/h2 was also reduced by week 24 (−0.19 kg/m2;
95% CI = −0.35 to −0.029; P = 0.02).
SMI increased by week 24 (P = 0.02), with men show-
ing a greater significant increase than women. Table 3
demonstrates body composition parameters at baseline
and week 24.
We also found an inverse relationship between ASM/h2,
SMI, and age in both men and women. However, the total
FM did not show similar trends (Figure 1).
Figure 2 shows the relationship between insulin sensi-
tivity index (QUICKI) and total FM, percentage FM, an-
droid FM, and gynoid FM.
In both men and women insulin sensitivity increased
as fat mass decreased.k by sex
Male
7) P-value Week 0 (n = 21) Week 24 (n = 14) P-value
0.03 2.35 ± 0.79 2.04 ± 0.78 0.001
0.02 3.37 ± 0.83 3.11 ± 0.90 0.004
0.45 0.70 ± 0.16 0.65 ± 0.12 0.015
0.47 1.21 ± 0.27 1.18 ± 0.24 0.25
0.027 7.68 ± 2.1 7.11 ± 2.03 0.022
0.006 8.75 ± 0.74 8.70 ± 0.92 0.38
0.29 0.31 ± 0.02 0.32 ± 0.02 0.69
0.6 0.038 ± 0.001 0.039 ± 0.001 0.005
0.015 21.88 ± 5.87 20.12 ± 6.00 0.003
0.000 27.11 ± 3.61 25.82 ± 4.90 0.08
0.014 53.6 ± 6.59 52.67 ± 7.60 0.17
0.65 2.60 ± 0.69 2.8 ± 0.71 0.041
Figure 1 The relationship between age and ASM/h2, SMI, and total FM in men and women. ASM: Appendicular skeletal muscle. h2: height
squared. SMI: Skeletal muscle index. FM: Fat Mass.
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Figure 2 The relationship between QUICKI (at the beginning of
the study) and total FM, Percentage of body fat, android FM,
and gynoid FM in men and women. FM: Fat Mass.
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Fasting blood sugar was improved significantly from
165.75 ± 60.75 mg/dL to 128.87 ± 40.1 (P = 0.0001). By
week 24, statistically significant reductions in HbA1c
(−1.34%; 95% CI = 1.99 to 0.68; P =0.000) and a significant
increase in insulin sensitivity (QUICKI) (+0.01; 95% CI =
0.001 to 0.027; P = 0.03) was shown. However, ΔHOMA-
IR was borderline statistically significant (P = 0.06).
Table 4 summarizes the changes in HbA1c, fasting
serum insulin, insulin resistance (HOMA-IR), and sensi-
tivity (QUICKI), by the end of the study.Exploratory endpoints
Based on ASM/h2 definition for sarcopenia, only one of
the participants could be diagnosed as afflicted with sarco-
penia. However, using the sarcopenia-residuals, 20% of the
women were considered to have sarcopenia. Considering
the low numbers of the male participants, we could not
apply the formula for the men. The SMI method picked
up a similar percentage of Class I (one SD below the mean
value of young adults) sarcopenia for the women. We did
not find Class II (two SDs below the mean value of young
adults) sarcopenia in our study population.
The women with sarcopenia were older and their
ASM/h2 was lower than non-sarcopenic women at base-
line (P = 0.001) and week 24 (P = 0.004). However, there
were not significant differences regarding metabolic indi-
ces and anthropometric variables at baseline and week 24
between sarcopenic and non-sarcopenic women.Discussion
Diabetes mellitus may be associated with increased risk
of sarcopenia which can result in physical disability and
metabolic disorders [18,19]. On the other hand, metfor-
min therapy can improve the parameters of body com-
position and insulin dynamics in people who are at risk
for type 2 diabetes [9]. The current study measured the
body composition in adults with newly diagnosed type 2
diabetes mellitus and explored the effect of metformin
therapy on various components of body composition, in-
sulin sensitivity, and glucose homeostasis. The results
showed significant changes in body composition, insulin
sensitivity and glucose homeostasis after 24 weeks of
treatment with metformin. The level of physical activity
remained unchanged suggesting that the alterations hap-
pened in body composition of the participants were
mainly due to the effect of the treatment.
We found a slight decrease in body weight in both sexes
though the changes of BMI remained statistically significant
only for the females probably due to predominance of the
women participated in the study. The weight reducing ef-
fect of metformin has been demonstrated previously as a
result of decreased food intake in a dose-dependent manner
Table 4 Glycemic status, insulin resistance and sensitivity at baseline and week 24
Week 0 Week 24 Mean difference ± SD 95% Confidence Interval P-value
HbA1c (%) 8.21±2.23 6.88±1.50 -1.34±2.05 (-1.99-0.68) 0.000
Fasting Insulin Level (μU/mL) 8.37±4.20 7.97±4.49 -0.4±5.49 (-1.45 2.26) 0.66
HOMA-IR 3.41±2.5 2.51±1.42 -0.90±2.79 (-1.84 0.45) 0.063
QUICKI 0.33±0.03 0.34±0.03 0.01±0.03 (0.001 0.027) 0.032
Paired t-test and Wilcoxon test was used.
HbA1c: Glycosylated Hemoglobin
HOMA-IR: Homeostatic Model Assessment-Insulin Resistance
QUICKI: Quantitative Insulin Sensitivity Check Index
Aghili et al. Journal of Diabetes & Metabolic Disorders 2014, 13:88 Page 7 of 8
http://www.jdmdonline.com/content/13/88[6] It modifies body composition in subjects with type 2
diabetes by reducing total body and abdominal fat [6,20].
In a study conducted by Kim et al., it was shown that
men with diabetes had decreased lean body mass and in-
creased body fat mass, even with similar BMI compared
with nondiabetic subjects. Based on the Framingham
and the National Health and Nutrition Examination
study III, the greater fat mass is associated with mobility
limitations and fat mass may be more important for mo-
bility than lean mass in older adults [21,22]. In addition,
it has been shown that in women with sarcopenia, lean
mass influenced mobility after accounting for body size
and fat mass [23]. It was also shown that regardless of
gender, people with diabetes had decreased SMI values
in KSOS study while SMI values increased after 6-
month metformin therapy in our study.
The insulin resistance level was reduced with metformin,
but borderline statistical significance was observed. Fur-
thermore, statistically significant change has been reported
in insulin sensitivity as a result of decreased fasting plasma
insulin and glucose level by metformin therapy. Compared
to the glucose clamp technique, that is considered to be
the gold standard method for directly measuring insulin
sensitivity in vivo, QUICKI is a simple alternative with ex-
cellent reproducibility. The correlation between QUICKI
and glucose clamp is significantly better than the correl-
ation between HOMA-IR and clamp technique [24]. How-
ever, there was no statistical difference in insulin level by
the end of the study. The increased insulin sensitivity ob-
served by metformin therapy was in parallel to the im-
provement in glucose homeostasis and HbA1c reduction
of 1.33% by the week 24. Our findings are in agreement
with several previous studies [9,25].
Considering the results of KSOS, the prevalence of
sarcopenia in patients with diabetes was significantly
higher than non-diabetic subjects. In subjects older than
60 years, a significant difference in prevalence of sarco-
penia between groups with and without diabetes was ob-
served in both gender while in the middle-aged group
(age 40 –59 years) this difference was observed only in
women. The result of our study is consistent with KSOS
that middle-aged women exhibited high prevalence of
sarcopenia.As shown in several previous studies, in general popu-
lation men lose greater skeletal muscle mass with aging
even with greater skeletal muscle mass compared to
women [26,27]; however, women with diabetes are par-
ticularly considered high risk for loss of skeletal muscle
mass [28]. These results suggest that type 2 diabetes
may be an important risk factor for sarcopenia, particu-
larly in women, considering its future impacts on quality
of life, physical disability and mortality. Although we
could not apply the definitions for men because of the
low numbers of the male participants in our study, it
seems this relationship in men could mainly be observed
in elderly population.
There is still a lack of consensus on definition of sarco-
penia [29]. Considering the three methods to define sarco-
penia, different rates have been estimated for sarcopenia
in our study. Based on the definition on ASM/h2, only one
of the participants could be diagnosed as afflicted with sar-
copenia. It has been reported that appendicular skeletal
muscle, i.e. ASM/h2 would lead to a lower cut points for
sarcopenia for the adults Asians [30] while based on the
sarcopenia-residuals and the SMI definitions for sarcope-
nia out of five female participants, one had sarcopenia.
Taking the results of this study into consideration, fur-
ther studies are needed to define a comprehensive method
to define sarcopenia in people with type 2 diabetes consid-
ering body size, gender and ethnicity. Furthermore, it is
needed to explore if female with diabetes are more prone
to develop sarcopenia.
In conclusion, administration of metformin for six
months had favorable effects on body composition, insu-
lin sensitivity, and glucose homeostasis in adults with
newly diagnosed type 2 diabetes and subsequently was
expected to postpone the incidence of sarcopenia espe-
cially in women with type 2 diabetes who are at higher
risk for loss of skeletal muscle mass.Limitations
Some limitations of this study include the limited num-
ber of the participants over the age of 60, small sample
size, and lack of objective data about nutritional pattern
of the participants.
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